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Abstract
 
The antiphospholipid syndrome (APS) is characterized by recurrent fetal loss, vascular throm-
bosis, and thrombocytopenia occurring in the presence of antiphospholipid (aPL) antibodies.
The pathogenesis of fetal loss and tissue injury in APS is incompletely understood, but is
thought to involve platelet and endothelial cell activation as well as procoagulant effects of aPL
antibodies acting directly on clotting pathway components. Recent studies have shown that
uncontrolled complement activation in the placenta leads to fetal death in utero. We hypothe-
sized that aPL antibodies activate complement in the placenta, generating split products that
mediate placental injury and lead to fetal loss and growth retardation. To test this hypothesis,
we used a murine model of APS in which pregnant mice are injected with human IgG con-
taining aPL antibodies. We found that inhibition of the complement cascade in vivo, using the
C3 convertase inhibitor complement receptor 1–related gene/protein y (Crry)-Ig, blocks fetal
loss and growth retardation. Furthermore, mice deficient in complement C3 were resistant to
fetal injury induced by aPL antibodies. While antigenic epitopes recognized by aPL antibodies
are important in the pathogenesis of APS, our data show that in vivo complement activation is
required for aPL antibody-induced fetal loss and growth retardation.
Key words: complement • anticardiolipin antibodies • pregnancy • thrombosis • lupus
 
Introduction
 
The antiphospholipid syndrome (APS)
 
* 
 
is characterized by
increased risk of vascular thrombosis involving venous, ar-
terial, and placental circulations. When thrombosis occurs
in the placenta, it is associated with poor obstetrical out-
comes, including fetal death and growth retardation. Pa-
tients with systemic lupus erythematosus are particularly
prone to APS, though it also occurs in individuals without
other manifestations of autoimmune disease.
Although it is clear that the specific antigenic reactivity of
antiphospholipid (aPL) antibodies is critical to their effect,
the pathogenic mechanisms that result in thrombosis and
tissue injury in vivo are incompletely understood. To better
understand these mechanisms, several murine models have
been developed and studied. In one model, passive transfer
of human IgG isolated from aPL antibody-positive sera
into pregnant mice induces fetal loss and growth retarda-
tion, thereby demonstrating the direct pathogenic role for
aPL antibodies (1). Murine and human monoclonal aPL
antibodies, which react specifically with the phospholipid-
 
binding protein 
 

 
2-glycoprotein I (
 

 
2GPI) or with an-
ionic phospholipids in the absence of 
 

 
2GPI, also deposit
in the placenta and produce fetal loss, growth retardation,
and necrosis (2–4). Recent in vitro studies in human pla-
centas have shown that trophoblast cell membranes behave
 
Address correspondence to Jane E. Salmon, Hospital for Special Surgery,
535 E. 70th St., New York, NY 10021. Phone: 212-606-1422; Fax: 212-
717-1192; E-mail: salmonj@hss.edu
 
*
 
Abbreviations used in this paper:
 
 aCL, anticardiolipin; aPL, antiphospho-
lipid; aPL-IgG, human IgG containing aPL antibody; APS, antiphospho-
lipid syndrome; 
 

 
2GPI,
 
 
 
2-glycoprotein I; Crry, complement receptor
1–related gene/protein y; MAC, membrane attach complex.
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as targets for 
 

 
2GPI-dependent and 
 

 
2GPI-independent
aPL antibodies (5), suggesting that these antibodies and
their effects are specifically targeted to the placenta.
Although the pathogenic potential of aPL antibodies that
recognize specific antigens has been demonstrated, their
ability to alter target antigen function has not, in and of it-
self, been shown to be sufficient to cause deleterious out-
comes, such as fetal loss. In addition, while experimental
models have emphasized the role of thrombosis in placental
tissue, histopathologic findings in placentas from women
with APS argue that other proinflammatory factors may
contribute to tissue injury (6, 7). Thus, although in vivo
and in vitro studies demonstrate that aPL antibodies trigger
activation of endothelial cells and platelets, the specific
mechanisms that link these events to tissue injury and, in
particular, to fetal loss and growth retardation remain un-
known (8–10).
Recent experiments in mice have underscored the im-
portance of fetal regulation of complement activation
to modulate potentially damaging maternal immune re-
sponses. These studies have focused on complement recep-
tor 1–related gene/protein y (Crry), a membrane-bound
intrinsic complement regulatory protein whose role is to
block C3 and C4 activation on self-membranes in mice
(11). That appropriate complement inhibition is an abso-
lute requirement for normal pregnancy has been demon-
strated by the finding that Crry deficiency in utero progres-
sively leads to embryonic death (12). 
 
Crry
 

 
/
 

 
 
 
embryos,
generated by gene targeting, have increased deposition of
activated C3 fragments and polymorphonuclear cells in
the ectoplacental cone and surrounding trophoectoderm
within the developing placenta. Although 
 
Crry
 

 
/
 

 
 embryos
are present in normal numbers on day 9 of gestation, they
show signs of growth retardation and all die by day 15 of
gestation. No live births have been found in cohorts of
 

 
250 newborns (12). Importantly, when the 
 
Crry
 

 
/
 

 
 
 
par-
ents are intercrossed with C3
 

 
/
 

 
 mice to generate 
 
C3
 

 
/
 

 
,
 
Crry
 

 
/
 

 
 embryos, there is complete rescue from this 100%
lethal outcome and live 
 
C3
 

 
/
 

 
, 
 
Crry
 

 
/
 

 
 
 
pups are born at a
normal Mendelian frequency (12). This outcome provides
proof that the 
 
Crry
 

 
/
 

 
 embryos die in utero due to their
inability to suppress spontaneous complement activation
and tissue damage mediated by C3.
In normal pregnancy, the human placenta appears to be
subjected to complement-mediated immune attack at the
maternal-fetal interface (13, 14). Although there is evi-
dence of activated complement in the placenta, it is likely
that in successful pregnancies uncontrolled complement ac-
tivation is prevented by complement inhibitory proteins,
such as decay-accelerating factor, membrane cofactor pro-
tein and CD59, which are present at high levels on tropho-
blast cells (15–20). Taken together, the murine and human
findings suggest that there is recognition of fetal tissues by
immune mechanisms that trigger complement fixation and
that in the presence of excessive complement activation or
in the absence of complement inhibitors the fetus is as risk
for injury.
 
We hypothesized that complement activation is a neces-
sary intermediary event in the pathogenesis of fetal loss as-
sociated with aPL antibodies. In addition to the rationale
outlined above, we have considered this possibility because
it is well-established that activated complement fragments
themselves have the capacity to bind and activate inflam-
matory and endothelial cells as well as induce a prothrom-
botic phenotype, either directly through the membrane
attach complex (MAC) or through C5a receptor (CD88)-
mediated effects (21, 22). In this setting, the effects of rec-
ognition of relevant target antigens by aPL antibodies and
the recruitment of the complement activating effector
function of the antibody Fc domain of the antibody would
both be necessary for pathogenic effects in vivo. We have
tested this hypothesis in the studies presented in this report.
Our results demonstrate that complement activation is re-
quired for the induction of fetal loss in vivo by aPL anti-
bodies and, therefore, that activation of complement is a
critical proximal effector mechanism in aPL antibody-
induced fetal injury.
 
Materials and Methods
 
Preparation of IgG.
 
Human IgG containing aPL antibodies
(aPL-IgG) was obtained from a patient with APS (characterized
by multiple cerebrovascular accidents, livedo reticularis, and the
lupus anticoagulant) with high titers of aPL IgG antibodies (
 

 
145
GPL U) identified through the Autoimmune Registry and Re-
pository of the Rheumatic Disease Service at the Hospital for
Special Surgery, New York, NY. IgG was purified by affinity
chromatography using Protein G sepharose chromatography col-
umns (Amersham Pharmacia Biotech). Control human IgG from
a healthy nonautoimmune individual was purified by an identical
method. Polyclonal mouse IgG control was obtained from Jack-
son ImmunoResearch Laboratories. All IgG samples were treated
to deplete endotoxin with Centriprep ultrafiltration devices (Mil-
lipore) and determined to be free of endotoxin contamination by
the limulus amebocyte lysate assay to a sensitivity of 0.06 EU/ml
(Associates of Cape Cod).
 
Detection of aPL Antibodies.
 
Levels of human anticardiolipin
(aCL) antibodies were measured by standard ELISA method per-
formed as described previously (23). The cardiolipin solid phase
assay was performed with serum samples or purified IgG fractions
at 1:50 dilution. GPL U (1 GPL U equals activity of 1 
 

 
g affinity
purified IgG aCL antibody) were calculated using international
standards supplied by the Rayne Institute (24). The purified IgG
containing aPL antibodies used herein demonstrated high reactiv-
ity in the aCL ELISA (82 GPL U).
To determine the in vivo t
 
1/2
 
 of human aPL antibodies in the
murine pregnancy model, mice were injected intraperitoneally
with aPL-IgG (10 mg) and serial blood samples were collected
at time points up to 36 h. Levels of human aCL antibodies in se-
rum of the mouse were measured using the standard ELISA at
1:5 dilution.
 
Complement Inhibitor Crry-Ig.
 
Crry-Ig was produced and pu-
rified using a previously described method (25). In brief, a soluble
chimeric protein was created that contains at the amino terminus
the extracytoplasmic five short consensus repeat domains of Crry
that retain classical and alternative pathway complement C3 con-
vertase inhibitory activity followed by the hinge, CH2 and CH3
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domains of the noncomplement fixing mouse IgG1 isotype. This
nonimmunogenic protein is produced in NS0 cells to a level of
 

 
50 mg/L, purified using a multicolumn FPLC method and has
been shown to effectively block complement activation by both
the classical and alternative pathways (11, 25). Previous studies
have also demonstrated that Crry-Ig ameliorates complement-
dependent in vivo effects in antiglomerular basement membrane–
induced glomerular injury (25) and ischemia-reperfusion induced
intestinal injury (unpublished data). For these studies, Crry-Ig
was purified under LPS-free conditions and had LPS levels 
 

 
0.4
ng/mg Crry-Ig using the limulus amebocyte lysate assay (Bio-
Whittaker).
 
Murine Pregnancy Model.
 
Female BALB/c mice (2–3-mo-old)
(Taconic) were allowed to mate with previously isolated males.
The presence of a vaginal plug was taken as an evidence for preg-
nancy. On days 8 and 12 of pregnancy female mice were treated
with intraperitoneal injections of aPL-IgG (10 mg), control hu-
man IgG (10 mg), or saline as described previously (1, 26). Some
mice received intraperitoneal injections of Crry-Ig (3 mg) or mu-
rine IgG (3 mg) every other day from days 8–12, an appropriate
timing as the t
 
1/2
 
 of Crry-Ig in vivo is 
 

 
40 h and this dose has re-
sulted in protection in other complement-dependent models.
Mice were killed on day 15 of pregnancy. Uteri were dissected,
fetuses and placentas were weighed, and frequency of fetal re-
sorption was calculated (number of resorptions divided by the to-
tal number of formed fetuses and resorptions). Resorption sites
are easily identified (see Fig. 2) and result from the loss of a previ-
ously viable fetus at that site. In healthy untreated mice, the fre-
quency of fetal resorption was 
 

 
0.05.
 
C3
 

 
/
 

 
 
 
mice were generated by intercrossing 
 
C3
 

 
/
 

 
 mice at F1
during a backcross to C57BL/6 and then propagating 
 
C3
 

 
/
 

 
progeny (27). The same aPL-IgG (10 mg) and control IgG (10
mg) were injected intraperitoneal on days 8 and 12 of pregnancy
into these mice. Control mice for these experiments were
B6129F1/Tac hybrid mice obtained from Taconic, which also
contain a mixture of C57BL/6 and Sv129 genes. Pregnancy out-
come was assessed as described above.
 
Immunohistochemistry.
 
Deciduas were removed and frozen
quickly in O.C.T. compound (Sakura) and 10 
 

 
m-thick sections
were cut. Endogenous peroxidase was quenched with 0.2%
H
 
2
 
O
 
2
 
 in methanol. Sections were first incubated with normal
rabbit serum to block nonspecific binding (Cappel), then incu-
bated with primary goat anti–mouse C3 (Cappel), followed by
rabbit anti–goat IgG conjugated to HRP (Sigma-Aldrich).
Bound HRP was detected with diaminobenzidine. Sections were
counterstained with 1% methylgreen and covered with mount-
ing medium (Cytoseal). Sections of frozen tissue were also
stained with H&E.
 
Analysis of Thrombus Dynamics.
 
To investigate the effects of
Crry-Ig on thrombophilia induced by aPL antibodies, male CD1
mice (25–30 g, 4–8-wk-old) (Charles River Laboratories) were
injected intraperitoneally with 500 
 

 
g of affinity purified human
aPL-IgG antibodies or control human IgG preparations at time 0
and 48 h. Methods for purification of the aPL antibodies has been
described previously (28). Half of the mice in each group were
treated with Crry-Ig (3 mg intraperitoneally at 0 and 48 h) and the
other half were treated with polyclonal murine IgG (3 mg intra-
peritoneally at 0 and 48 h). Surgical procedures to study thrombus
dynamics were performed 72 h after the first aPL-IgG (or control
human IgG) injection. ACL antibody titers were also measured at
that time.
The mouse model of thrombosis formation employed in this
study has been described in detail (28, 29). Briefly, mice were
anesthetized, and the right femoral vein was exposed, resulting in
a 0.5-cm segment of vein free for manipulation and observation.
The vein was pinched with a pressure of 1,500 g/mm
 
2
 
 to intro-
duce a standardized injury that induced a clot. Clot formation
and dissolution in the trans-illuminated vein were visualized with
a microscope equipped with a closed-circuit video system (in-
cluding a color monitor and a recorder). Thrombus size (in
square micrometers) was measured 1 min after the pinch injury
by freezing the digitized image and tracing the outer margin of
the thrombus. 3–5 thrombi were successfully induced in each an-
imal, and mean values were computed.
 
Data Analysis.
 
Data are expressed as mean 
 

 
 SD. The Stu-
dent’s unpaired 
 
t
 
 test was used to compare the frequency of fetal
resorption, fetal weights, thrombus size, and aPL titers between
groups. In all analyses, a probability of 
 

 
0.05 was used to reject
the null hypothesis.
Results
 
Crry-Ig Ameliorates aPL Antibody-induced Pregnancy Loss in
BALB/c Mice.
 
To determine whether complement acti-
vation is necessary for aPL-IgG–induced fetal loss, we first
used Crry-Ig to block complement activation in vivo. No
soluble forms of Crry are found in mice, and treatment of
mice with this recombinant protein results in nearly com-
plete complement inhibition in vivo (25). BALB/c mice
were treated with aPL-IgG (10 mg), control human IgG
(10 mg), or saline intraperitoneally on days 8 and 12 of
pregnancy. Half of the mice received Crry-Ig (3 mg intra-
peritoneally) every other day from days 8–12. On day 15,
pregnant mice were killed, and the uterine contents were
evaluated.
Treatment with aPL-IgG caused a nearly fourfold in-
crease in the frequency of fetal resorption, while simulta-
neous treatment with Crry-Ig prevented aPL antibody-
induced pregnancy losses (Fig. 1 A). Fig. 2 (top) shows a
representative placenta from an aPL antibody–treated
mouse. The fetuses are small and two fetal resorptions are
seen. In contrast, Fig. 2 (bottom) demonstrates a uterus
from an aPL antibody-treated mouse that received Crry-Ig.
Here, the fetal sacs are larger and no resorptions are seen.
Crry-Ig also prevented aPL antibody–mediated growth
retardation in the surviving fetuses (Fig. 1 B). Treatment
with aPL-IgG alone resulted in a 45% decrease in fetal
weight, whereas in mice treated with aPL-IgG and Crry-Ig
the weights of fetuses were nearly identical to those of con-
trol mice (Fig. 1 B). Crry-Ig prevented the aPL-IgG induced
growth retardation in the fetus and in the placental elements.
Importantly, Crry-Ig had no effect on either the frequency
of fetal resorption or on fetal size in the absence of aPL anti-
body. Therefore, its protective effects are dependent on the
presence of aPL antibodies in the injected human IgG.
That Crry-Ig ameliorates these effects of aPL-IgG on fe-
tal resorption and fetal weight by complement inhibition
was tested in a second series of experiments. Pregnant
BALB/c mice injected with aPL-IgG were treated with 3
mg of either Crry-Ig or control murine polyclonal IgG. In
these studies, the capacity of Crry-Ig to specifically prevent
aPL antibody-induced fetal resorption was confirmed (Ta-
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ble I). Mice treated with aPL-IgG along with murine IgG
showed a threefold increase in fetal resorption as compared
with mice treated with control human IgG and murine
IgG. Murine IgG had no effect on either induction of fetal
loss or growth retardation by aPL-IgG. In contrast, Crry-Ig
consistently prevented fetal loss and impaired growth asso-
ciated with aPL antibodies (Table I). That results from ex-
periments with monoclonal human aPL antibodies are sim-
ilar to results using polyclonal aPL antibodies (data not
shown), indicates that antibodies reactive with aPL, rather
than xenoreactive antibodies which may be present in
polyclonal human IgG, initiate complement activation, and
fetal damage in our model.
To exclude the possibility that Crry-Ig altered the han-
dling of aPL antibodies, we measured levels of human aCL-
 
reactive IgG in mice treated with Crry-Ig and control mu-
rine IgG. The serum t
 
1/2
 
 (3.7 
 

 
 0.9 h vs. 4.1 
 

 
 0.5 h, re-
spectively), and peak levels (65 
 

 
 18 GPL U vs. 68 
 

 
 22 U,
respectively) were indistinguishable.
 
Immunohistological Analysis of aPL Antibody-induced Fetal
Loss.
 
Spontaneous maternal complement activation at
the fetal-maternal interface presents a danger to the devel-
oping fetus. In 
 
Crry
 

 
/
 

 
 mice complement activation causes
fetal death (12). To determine whether excessive comple-
ment activation occurs within the placenta in aPL-treated
mice, we conducted immunohistological analyses of de-
cidua 90 min after the first treatment (day 8 of pregnancy)
with aPL-Ig or control IgG. In preliminary experiments
we confirmed that human IgG was deposited in the de-
cidua of mice treated with aPL-IgG or with aPL-IgG and
Crry-Ig, whereas there was no evidence of IgG deposition
in mice treated with control human IgG (data not shown).
In aPL-treated mice, the decidua was abnormal morpho-
logically, showing focal necrosis and apoptosis with neu-
trophil infiltrates and loss of the fetal membrane elements
(Fig. 3). This was in contrast to relatively normal appearing
decidua of mice treated with control human IgG or aPL-
IgG and Crry-Ig.
Staining with antibodies against the murine complement
component C3 revealed extensive complement deposition
within the decidua and on the extraembryonic membranes
in the mice treated with aPL-IgG (Fig. 4). In the mice
treated with control human IgG small amounts of C3 stain-
ing were detectable, mostly in the extraembryonic tissues,
but the decidua was not inflamed and had normal cellular
elements (Fig. 4). We infer that as a consequence of the
large amount of activated complement produced when
aPL-IgG is present within the decidua, membrane bound
complement inhibitors, such as Crry, are unable to prevent
complement deposition.
Treatment with Crry-Ig at the time of administration of
aPL-Ig completely prevented C3 deposition on the decidua
(Fig. 4). In mice treated with aPL-IgG and Crry-Ig, there
was no infiltration of neutrophils, and there was normal fe-
Figure 1. Crry-Ig ameliorates aPL-IgG–induced pregnancy complica-
tions. Female BALB/c mice were treated intraperitoneally with IgG (10 mg)
from a patient with APS (aPL), normal human IgG (Cntrl IgG), or saline
(Vehicle) on days 8 and 12 of pregnancy. Some the mice received Crry-Ig
(3 mg intraperitoneal) every other day from days 8–12. Mice were killed
on day 15 of pregnancy, uteri were dissected, fetuses were weighed, and
frequency of fetal resorption calculated (number of resorptions/number of
fetuses plus number of resorptions). There were six mice in each group.
(A) Treatment with aPL-IgG caused an increase in fetal resorptions com-
pared with vehicle or control human IgG (*P  0.05) which was pre-
vented by Crry-Ig (*aPL versus aPL plus Crry-Ig; P  0.05). (B) aPL-IgG
caused fetal growth retardation (*aPL versus Cntrl IgG; P  0.01) which
was also prevented by Crry-Ig (*aPL versus aPL plus Crry-Ig; P  0.01).
Figure 2. Effects of Crry-Ig on aPL antibody-induced fetal resorption.
Representative uteri from BALB/c mice killed at day 15 of pregnancy are
shown. The top panel, from a mouse treated with aPL-IgG and murine
IgG, shows eight fetuses and deciduas of varying size and two resorptions
(arrows). The bottom panel, from a mouse treated with aPL and Crry-Ig,
contains larger fetuses with deciduas and no resorptions.
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tal development (Fig. 3). Our results indicate that placental
complement deposition and extensive inflammation is asso-
ciated with aPL-treatment and that these effectors can be
inhibited by Crry-Ig.
 
C3-deficient Mice Are Protected from aPL-associated Fetal Re-
sorption and Growth Retardation.
 
As an alternate approach
to test the hypothesis that complement activation is re-
quired for aPL-induced pregnancy complications, we per-
formed studies in mice deficient in complement compo-
nent C3. First, aPL-IgG was shown to result in poor
pregnancy outcomes in the B6129F1 hybrid mice, the
control strain for the 
 
C3
 

 
/
 

 
 mice at the F1 backcross to
 
C57BL/6. Similar to BALB/c mice, there was a 
 

 
4-fold
increase in the frequency of fetal resorption (Fig. 5). In ad-
dition, Crry-Ig treatment, when compared with the ad-
ministration of control mouse IgG, specifically prevented
this outcome (Fig. 5 A) as well as growth retardation (Fig.
5 B).
These experiments established the validity of using hy-
brid mice containing 
 

 
50% each of C57BL/6 and Sv129
genes. As predicted by experiments with Crry-Ig, aPL-
IgG did not increase the frequency of fetal resorption in
 
C3
 

 
/
 

 
 mice on the same genetic background (Fig. 5 A).
The protective effects of a complete lack of complement
 
Table I.
 
Crry-Ig Specifically Prevents aPL Antibody-induced Fetal Resorption and Growth Retardation
 
Human IgG source: aPL aPL Cntrl IgG Cntrl IgG
Mouse reagent: mIgG Crry-Ig mIgG Crry-Ig
Number of mice 11 14 10 11
Frequency of fetal resorption 0.29 
 

 
 0.09
 
a
 
0.08 
 

 
 0.03 0.10
 
  
 
0.05 0.08 
 

 
 0.03
Fetal weight (mg) 171 
 

 
 27
 
a
 
256 
 

 
 38 273 
 

 
 32 281 
 

 
 34
Female BALB/c mice were given aPL-IgG (10 mg) or normal human IgG (Cntrl IgG) (10 mg) intraperitoneally on days 8 and 12 of pregnancy. Mice
also received either Crry-Ig (3 mg) or polyclonal murine IgG (mIgG) (3 mg) intraperitoneally every other day from days 8–12. Mice were killed on
day 15 of pregnancy, uteri were dissected, fetuses were weighed, and frequency of fetal resorption calculated (number of resorptions/number of fetuses
plus number of resorptions). Treatment with aPL-IgG caused an increase in fetal resorptions and a decrease in fetal weight (
 
a
 
aPL plus mIgG versus
Cntrl IgG plus mIgG;
 
 P
 
 
 
 0.001) which was prevented by Crry-Ig (
 
a
 
aPL plus mIgG versus aPL plus Crry-Ig; 
 
P 
 
 
 
0.001). Treatment with mIgG did
not affect either pregnancy outcome.
Figure 3. APL antibody-induced necrosis and in-
filtration of neutrophils in decidual tissue is pre-
vented by Crry-Ig. Pregnant mice (day 8) were in-
jected with control human IgG (A and D), aPL-IgG
(B and E), or aPL-IgG and Crry-Ig (C and F), and
uteri were removed after 90 min. In mice treated
with aPL-IgG there was increased density of cells
and focal necrosis within the decidual tissue (B) and
clumping, apoptosis, and scattered clusters of neu-
trophils (arrows) throughout (E). Decidual tissue
from mice treated with aPL-IgG and Crry-Ig was
similar to mice treated with control Ig, showing
uniform, sparse cellularity (A and C) and normal
appearing trophoblastic cells (D and F). Sections
were stained with H&E. (A–C) Original magnifica-
tion: 	10; (D–F) original magnification: 	40.
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C3 were also found when fetal weights were examined
(Fig. 5 B). Serum t
 
1/2
 
 and peak levels of human aPL anti-
bodies were comparable in 
 
C3
 

 
/
 

 
 and 
 
C3
 

 
/
 

 
 mice (t
 
1/2
 
3.1 
 

 
 0.8 h vs. 3.5 
 

 
 0.7 h, respectively; peak aCL levels
78 
 

 
 12 vs. 83 
 

 
 19 GPL U). These data eliminate the
possibility that differences in handling antibodies in the
two strains of mice account for differences in aPL-IgG–
mediated pathogenicity.
Thus, using three distinct approaches, a specific comple-
ment inhibitor (Crry-Ig), genetically deficient mice (
 
C3
 

 
/
 

 
),
and immunohistochemical evidence that absence of C3
deposition in Crry-Ig–treated mice correlated with im-
proved outcomes, we have demonstrated that complement
activation is required for fetal loss and growth retardation
in this murine model of APS.
 
Crry-Ig Inhibits aPL Antibody-induced Enhancement of
Thrombosis.
 
To better understand the mechanism by
which Crry-Ig protects against aPL-induced fetal loss, we
tested the hypothesis that complement inhibition blocks
thrombosis generation in vivo. Because complement frag-
ments (such as C3a or C5a) can directly activate endothelial
cells by binding to cell surface receptors or indirectly acti-
vate endothelial cells by binding to receptors on neigh-
boring phagocytes or platelets, they may induce a pro-
thrombotic phenotype (30, 31). We predicted that this
thrombophilic state would be prevented if complement ac-
tivation were inhibited. An in vivo microcirculation model
had been developed and used to show that aPL-IgG anti-
bodies induce endothelial cell activation and enhance and
accelerate thrombus formation in the presence of a vascular
injury (28, 29, 32). We employed this experimental model
Figure 4. Complement activation in decidual tissue of aPL antibody-
treated mice is prevented by Crry-Ig. Sections of decidual tissue from
mice injected with control human IgG (A), aPL-IgG (B), or aPL-IgG and
Crry-Ig (C) as described in Fig. 3 were stained with antibody to mouse
C3. In the aPL-IgG treated mice (B), there was extensive C3 deposition
in the decidua and extraembryonic membranes. In contrast, the decidual
tissues from mice treated with control IgG (A) or aPL-IgG and Crry-Ig
(C) show minimal staining for C3 with more intense staining on the ex-
traembryonic tissues (arrows). Original magnification: 	10.
Figure 5. C3-deficient mice are protected from aPL antibody-induced
pregnancy complications. C3/ mice (B6/Sv129F1) were treated with
aPL-IgG (10 mg intraperitoneally) (aPL) or normal human IgG (Cntrl
IgG) on days 8 and 12 of pregnancy. Half of the mice in each group re-
ceived Crry-Ig (3 mg intraperitoneally) every other day from days 8–12
and half received control murine IgG (mIgG). C3/ mice were treated
with either aPL-IgG or normal human IgG. Pregnancy outcomes were
assessed as described in the legend for Fig. 1. There were 10–14 mice in
each experimental group. (A) Analysis of the four groups of C3/ mice
shows that treatment with aPL-IgG caused an increase in frequency of fe-
tal resorptions in this strain (*aPL plus mIgG versus Cntrl IgG plus mIgG;
P  0.01), while C3/ were protected from aPL-induced pregnancy loss
(aPL versus Cntrl IgG; P 
 NS). In the C3/ mice, Crry-Ig prevented
aPL-induced fetal resorption (*aPL plus mIgG versus aPL plus Crry-Ig;
P  0.01). (B) Similarly, aPL treatment caused a decrease in fetal weight
in C3/ mice (*aPL plus mIgG versus Cntrl IgG plus mIgG; P  0.01)
which was absent in C3/ mice, and this was ameliorated by Crry-Ig
(*aPL plus mIgG versus aPL plus Crry-Ig; P  0.01).
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of APS to examine the effects of complement inhibition on
aPL-IgG–induced thrombus formation. CD1 male mice
were treated with aPL-IgG or control human IgG, and half
the mice in each of the two groups were treated with Crry-
Ig and half with polyclonal murine IgG. 72 h after the first
injection, the dynamics of surgically induced thrombus for-
mation were measured in the right femoral vein by a stan-
dard pinch injury. There was a fivefold increase in the av-
erage size of thrombi in mice treated with aPL-IgG
compared with those treated with control IgG (Fig. 6).
Whereas Crry-Ig did not alter thrombus size in mice
treated with control human IgG, administration of Crry-Ig
significantly decreased aPL-induced enhancement of throm-
bosis, resulting in values near those of the controls (Fig. 6).
As before, there was no difference in the peak levels of hu-
man aCL activity between mice treated with Crry-Ig and
mice treated with control murine IgG (25 
 

 
 14 U vs. 31 
 

 
16 GPL U, respectively), excluding the possibility that the
inhibitory action of Crry-Ig was related to alterations in
levels of aPL antibodies.
In sum, these results demonstrate that complement acti-
vation is a central mechanism contributing to aPL anti-
body-induced thrombophilia, pregnancy loss, and fetal
growth retardation. Although the cause of tissue injury in
this disease is likely multifactoral, we have shown that
complement activation is an absolute requirement for two
of the most deleterious phenotypic outcomes in this condi-
tion and, therefore, that this pathway acts upstream of other
effector mechanisms.
 
Discussion
 
In a murine model of APS induced by passive transfer of
human aPL-IgG antibodies, we have made the unantici-
pated finding that complement blockade at the point of C3
activation prevents fetal loss and growth retardation. In this
in vivo model, using Crry-Ig, an exogenously administered
inhibitor of C3 activation, and using mice deficient in C3,
we have shown that complement activation plays an essen-
tial and causative role in fetal loss and tissue injury. Our
studies demonstrate that, while the nature of the antigens
recognized by aPL antibodies is clearly important, comple-
ment activation is the major effector mechanism by which
these antibodies mediate tissue injury.
In the first series of experiments, we used Crry-Ig, a C3
convertase inhibitor that blocks activation of C3 by both
the classical and alternative pathways. Because Crry-Ig is a
chimera between the complement regulatory domains of
Crry and the Fc domain of mouse IgG1, we compared its
effects with those of polyclonal mouse IgG. That treatment
with control murine IgG did not prevent the deleterious
effects of aPL antibodies on fetal growth and survival indi-
cates that the ability of Crry-Ig to bind to Fc
 

 
 receptors or
to mediate other nonspecific effects does not determine this
biologic outcome. Furthermore, measurement of aPL titers
in Crry-Ig-treated and control mice demonstrated that
Crry-Ig did not act simply as a competitive inhibitor of aPL
antibody. Rather, our results argue that fetal damage is
averted through Crry-Ig–mediated blockade of C3 activa-
tion. Indeed, our observations that Crry-Ig prevents C3
deposition within the decidua and that 
 
C3
 

 
/
 

 
 
 
mice are
protected from APS support our conclusion that the critical
in vivo effect of Crry-Ig is related to inhibition of comple-
ment activation. In sum, using several strategies, we have
shown that complement activation is the mediator of injury
in this model of APS.
It is important to note that our results are also consistent
with the observation that inactivation of the endogenous
gene encoding for Crry is associated with inappropriate
complement activation and fetal loss (12). The requirement
for an inhibitor of complement suggested that complement
activation is present in normal pregnancy. Indeed, we
found small amounts of C3 deposition within the placentas
of normal pregnant mice treated with control human IgG.
However, in mice treated with aPL-IgG, C3 deposition
was markedly increased. Thus, it appears that excessive
complement activation in the placenta, whether due to a
lack of a critical regulatory protein such as Crry or the pres-
ence of complement-fixing aPL antibodies, places the fetus
at risk for growth retardation or death.
Based on our findings, we propose the following mecha-
nism for the pathogenic effects of aPL antibodies on preg-
nancy outcome. First, aPL antibodies are preferentially tar-
geted to the placenta. This has been suggested by several
previous in vitro studies that showed that placental tropho-
Figure 6. aPL-IgG–induced thrombophilia is inhibited
by Crry-Ig. CD-1 mice were injected intraperitoneal with
affinity purified aPL-IgG (aPL) or normal human (Cntrl
IgG) at 0 h and 48 h. Half the mice in each group received
Crry-Ig, and half the mice received control murine IgG
(mIgG). At 72 h after the first injection, surgically induced
thrombus formation was measured as described in Materi-
als and Methods. There were 11–14 mice in each experi-
mental group. Treatment with aPL-IgG caused an increase
in thrombus size (*aPL plus mIgG versus Cntrl IgG plus
mIgG; P  0.05), while Crry-Ig prevented aPL-induced
enhancement of thrombosis (*aPL plus mIgG versus aPL
plus Crry-Ig; P  0.05; Cntrl IgG plus Crry-Ig versus aPL
plus Crry-Ig; P 
 NS).
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blast cell membranes bind both 
 

 
2GPI-dependent and
 

 
2GPI-independent aPL antibodies (5, 33). Second, pla-
cental aPL antibodies promote platelet and endothelial
cell activation and directly induce procoagulant activity
through interaction with elements of the coagulation path-
way (8, 32, 33–36). This activity, however, does not appear
to be sufficient to cause fetal loss or growth retardation,
perhaps because of counterregulatory mechanisms. Activa-
tion of the complement pathway by aPL-IgG amplifies
these effects by stimulating the generation of further potent
mediators of platelet and endothelial cell activation, includ-
ing C3a, C5a, and the C5b-9 MAC. The addition of these
complement activation products causes thrombosis, tissue
hypoxia, and inflammation within the placenta, and ulti-
mately leads to fetal injury. Depending on the extent of
damage, either death in utero or fetal growth retardation
results. That Crry-Ig blocks thrombosis initiated by aPL
antibodies in an in vivo vascular injury model is consistent
with our suggestion that complement activation products
play a pivotal role in aPL-induced injury.
Though it is not clear from our results which comple-
ment components or receptors are primarily responsible for
fetal loss mediated by aPL antibodies, likely candidates in-
clude C3a and/or C5a or the C5b-9 MAC. C5a and the
C5b-9 MAC have well described effects on platelets and
endothelial cells (31, 36). Future studies in mice deficient
in specific complement components and receptors may
identify the particular complement activation products that
promote fetal loss and growth retardation.
Our model of the pathogenesis of fetal wastage in APS is
fundamentally different from that previously presented by
Merrill et al. (37). These authors proposed that 
 

 
2GPI and
C4-binding protein, a complement inhibitor that also reg-
ulates the clotting pathway, compete for binding to protein
S. Their hypothesis is focused on the activities of C4-bind-
ing protein that are not related to complement. Instead, we
propose that pathogenic aPL antibodies, in addition to their
direct effects on platelet and endothelial cell targets, gener-
ate complement split products and MAC which cause in-
crease tissue injury.
To extend our model of the mechanisms of fetal damage
in APS to patients with this syndrome, it is important that
our findings are consistent with clinical and laboratory fea-
tures of patients with APS and recurrent fetal loss. We be-
lieve that they are. Histopathologic findings in placentas
from women with APS argue that proinflammatory factors
contribute to injury (6, 7). Previous studies have provided
evidence for complement activation in the serum of preg-
nant patients with systemic lupus erythematosus (38), and
indicate that specific patterns of complement activation are
associated with either a flare of disease or preeclampsia (39).
In addition, elevated complement split products have been
detected in the serum of patients with other manifestations
of aPL-associated disease, such as stroke and transient
ischemic attack (40). Finally, recent studies using a novel
assay in which complement-fixing human aPL can be dis-
tinguished from noncomplement-fixing aPL antibodies have
shown that complement-fixing antibodies are highly asso-
ciated with thrombosis and/or recurrent fetal loss (41).
Thus, we believe that our results are consistent with the
findings in patients with aPL antibody-associated recurrent
fetal loss.
Treatment of patients with recurrent aPL antibody-asso-
ciated fetal loss is difficult and requires the use of several an-
ticoagulation strategies and, in some cases, immunosup-
pression. Despite these measures, many patients continue to
suffer recurrent spontaneous abortions (42). Given the
finding that the complement inhibitor Crry-Ig protects
mice from the effects of human aPL antibody, it is possible
that a similar strategy would provide an effective new ther-
apy for pregnancy loss in patients. Likewise, it is possible
that aPL antibody-associated thrombosis in other organs is
also mediated by complement activation and may be ame-
nable to this therapeutic approach.
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